Neoantigen × AI
Daily research signal
№49Brief

Moderna, Merck prep filing for personalized melanoma vaccine

Personalized neoantigen vaccines hit two fronts today: Evaxion's AI-designed EVX-01 posted paired immune and durable clinical response data with pembrolizumab in advanced melanoma, while Moderna and Merck confirmed they are preparing a regulatory filing for intismeran autogene.OncLiveDrug Discovery & Development

Moderna's raised 2026 guidance shows the oncology pipeline, not COVID, is now the growth story investors are pricing.Drug Discovery & DevelopmentYahoo Finance Melanoma — metastatic and adjuvant — remains the proving ground for the modality.

3new stories
ClinicaltodayNew

EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma - OncLive

Evaxion presented translational data at SITC 2026 from its phase 2 trial (NCT05309421) of EVX-01, an AI-designed personalized peptide vaccine, plus pembrolizumab in advanced melanoma: in the single-arm study (n=16, predominantly stage IV), ORR was 75% with 25% complete responses by RECIST 1.1, and 89% of 118 vaccine neoantigens induced T-cell responses, with sustained effector memory T-cell enrichment. The data tie the company's neoantigen-selection platform to both immunologic activity and durable responses in a late-line setting. The cohort is small and uncontrolled, but the paired immune-correlate package is the kind of evidence partners and regulators look for as the combination moves forward.

news · today · OncLive

02

01
CommercialyesterdayNew

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3 - Drug Discovery & Development

Moderna said in its November 6 earnings release that it is preparing to seek approval for intismeran autogene, its personalized mRNA cancer vaccine with Merck, designed to prevent melanoma recurrence after surgery by encoding up to 34 patient-specific neoantigens. The partnership dates to 2016, the phase 2b melanoma study has been enrolling since 2019, and Merck paid $250 million in 2022 to exercise its option, with costs and profits split equally. A filing would give the Moderna-Merck alliance a shot at commercializing the field's most advanced big-pharma-backed program — and Moderna, whose revenue fell roughly 90% from $19.3 billion in 2022 to $1.9 billion in 2025 as COVID demand receded, a revenue diversification path; shares are up more than 700% this year in a rally Barron's attributes partly to the cancer vaccine.

news · yesterday · Drug Discovery & Development
02
CommercialyesterdayNew

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas - Yahoo Finance

Moderna raised its full-year 2026 revenue growth forecast to 15–25%, up from a prior outlook of up to 10%, after swinging to a Q3 profit on strong international COVID vaccine demand and partnership payments. The company also has its newly FDA-cleared flu vaccine mFlusiva — the first mRNA-based seasonal flu authorization, for adults 50 and older — with a limited US launch planned for the 2026-27 season. The improved near-term cash picture funds the pivot to new products, with investors viewing the personalized cancer vaccine candidate as key to the long-term growth of the mRNA platform.

news · yesterday · Yahoo Finance